Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Drug Profile

Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Alternative Names: Dexamethasone sodium phosphate - Enceladus Pharmaceuticals; Enc 0313; Liposomal dexamethasone - Enceladus Pharmaceuticals; Oncocort; PEG-liposomal dexamethasone sodium phosphate

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enceladus Pharmaceuticals
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Prostate cancer

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 08 Nov 2016 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Monotherapy, Hormone refractory) in Netherlands (IV) (EudraCT2016-003121-42)
  • 12 Oct 2016 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy) in Germany (IV) (EudraCT2014-005137-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top